SFNP 2022 – Alnylam takes heart from its Onpattro follow-on

Vutrisiran, Alnylam’s more convenient follow-on to Onpattro, has looked approvable for a while in the polyneuropathy subtype of hereditary ATTR amyloidosis. But investors really want to know if vutrisiran – and Onpattro – can also get to market in the cardiomyopathy subtype, a bigger indication.